tert-butyl 6-hydroxy-3-phenyl-1H-indazole-1-carboxylate | 1204772-94-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 6-hydroxy-3-phenyl-1H-indazole-1-carboxylate
• 英文别名: t-butyl 6-hydroxy-3-phenyl-1H-indazole-1-carboxylate；Tert-butyl 6-hydroxy-3-phenylindazole-1-carboxylate
• CAS: 1204772-94-0
• 化学式: C₁₈H₁₈N₂O₃
• 分子量: 310.353
• InChiKey: FLNSDZYCZKALEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  64.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 6-hydroxy-3-phenyl-1H-indazole-1-carboxylate 在 三氟乙酸 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 4.0h， 生成 6-Hydroxy-3-phenyl-1H-indazole
  参考文献：
  名称：

  BICYCLIC NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS

  摘要：

  提供一种由以下式（1）表示的含氮双环杂环化合物。当该化合物或其盐被用于人类或动物时，该化合物对EP1受体具有强烈的拮抗作用，并且可用作预防和/或治疗膀胱过度活跃的药物的活性成分。该化合物还可用作预防和/或治疗频繁排尿、尿急或尿失禁等症状的药物的活性成分。

  公开号：

  US20100029733A1
• 作为产物：
  描述：

  6-氟(1H)吲唑 在 咪唑 、 4-二甲氨基吡啶 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium tert-butylate 、 水 、 碘 、 三乙胺 、 三(邻甲基苯基)磷 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.67h， 生成 tert-butyl 6-hydroxy-3-phenyl-1H-indazole-1-carboxylate
  参考文献：
  名称：

  Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β₃-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects

  摘要：

  Novel indazole derivatives were prepared and evaluated for their biological activity and cardiovascular safety profile as human A-adrenergic receptor (AR) agonists. Although the initial hit compound 5 exhibited significant beta(3)-AR agonistic activity (EC50 = 21 nM), it also exhibited agonistic activity at the alpha(1A)-AR (EC50 = 219 nM, selectivity: alpha(1A)/beta(3) = 10-fold). The major metabolite of 5, which was an oxidative product at the indazole 3-methyl moiety, gave a clue to a strategy for improvement of the selectivity for beta(3)-AR agonistic activity versus au-AR agonistic activity. Thus, modification of the 3-substituent of the indazole moiety effectively improved the selectivity to develop compound 11 with potent beta(3)-AR agonistic activity (EC50 = 13 nM) and high selectivity (alpha(1A)/beta(3) = >769-fold). Compound 11 was also inactive toward beta(1) and beta(2)-ARs and showed dose dependent beta(3)-AR mediated relaxation of marmoset urinary bladder smooth muscle, while it did not obviously affect heart rate or blood pressure (iv, 3 mg/kg) in anesthetized rats.

  DOI：

  10.1021/acs.jmedchem.5b00638

文献信息

• NITROGENATED BICYCLIC HETEROCYCLIC COMPOUND
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP2298767A1

  公开（公告）日：2011-03-23

  A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 receptors, and is useful, for example, as an active ingredient of a medicine for the prevention and/or treatment of overactive bladder. The compound is also useful as an active ingredient of a medicine for the prevention and/or treatment of symptoms such as frequency urinary, urinary urgency, or urinary incontinence.

  本发明提供了一种由下式（1）表示的含氮双环杂环化合物。 当该化合物或其盐被施用于人或动物时，该化合物对 EP1 受体具有很强的拮抗作用，例如可用作预防和/或治疗膀胱过度活动症的药物的活性成分。 该化合物还可用作预防和/或治疗尿频、尿急或尿失禁等症状的药物的活性成分。
• US7994202B2
  申请人：——

  公开号：US7994202B2

  公开（公告）日：2011-08-09